SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details)			1 Months Ended			12 Months Ended
	Jul. 02, 2021 USD ($) $ / shares	May 13, 2021 USD ($)	Jul. 23, 2018 USD ($)	Oct. 19, 2017 USD ($)	Oct. 31, 2015	Dec. 31, 2022 USD ($) item $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 shares	Jun. 30, 2021 USD ($)	Dec. 01, 2016
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 0.001	$ 0.001
Accounts receivable - Trade						$ 4,586,000	$ 3,442,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares						34,097,716	28,502,017	22,850,682
Fiocruz
Significant Accounting Policies [Line Items]
Accounts receivable - Trade						$ 2,300,000
Chiesi
Significant Accounting Policies [Line Items]
Accounts receivable - Trade						1,200,000
Pfizer
Significant Accounting Policies [Line Items]
Accounts receivable - Trade						1,100,000
2021 Notes
Significant Accounting Policies [Line Items]
Aggregate principal amount						$ 0	$ 0
Interest rate (as a percent)						7.50%				7.50%
2024 Notes
Significant Accounting Policies [Line Items]
Aggregate principal amount						$ 28,750,000
Interest rate (as a percent)						7.50%
Minimum cash balance required						$ 7,500,000
Minimum
Significant Accounting Policies [Line Items]
Tax Rate Assumption Related To Deferred Tax Difference Reversal						23.00%
Maximum
Significant Accounting Policies [Line Items]
Tax Rate Assumption Related To Deferred Tax Difference Reversal						21.00%
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues Expenses Sharing Percentage					100.00%
Chiesi US Agreement and Chiesi Ex-US Agreement
Significant Accounting Policies [Line Items]
Non-refundable Payment Receivable			$ 25,000,000.0	$ 25,000,000.0		$ 50,000,000.0
Agreement Amendment Payment Receivable						$ 10,000,000.0			$ 10,000,000.0
Performance obligation number | item						2
Chiesi US Agreement
Significant Accounting Policies [Line Items]
Non-refundable Payment Receivable			25,000,000.0
Additional Amounts Payable To Cover Development Costs			20,000,000.0
Additional amount payable for achievement of regulatory and commercial milestones			$ 760,000,000.0			$ 735,000,000.0
Chiesi US Agreement | Minimum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage			15.00%			15.00%
Chiesi US Agreement | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage			40.00%			40.00%
Chiesi Ex-US Agreement
Significant Accounting Policies [Line Items]
Non-refundable Payment Receivable				25,000,000.0
Additional Amounts Payable To Cover Development Costs				25,000,000.0
Additional amount payable for achievement of regulatory and commercial milestones				$ 320,000,000.0
Change in amount receivable for achievement of regulatory and commercial milestones		$ 25,000,000.0
Agreement Amendment Payment Receivable		$ 10,000,000.0
Chiesi Ex-US Agreement | Minimum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage				15.00%		15.00%
Chiesi Ex-US Agreement | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage				35.00%		35.00%
ATM Shares
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.001
Sale of stock, maximum offering price	$ 20,000,000.0					$ 11,300,000